Ask AI
ES SCLC 1L Therapy

CE / CME

Enhancing Outcomes in Extensive-Stage Small-Cell Lung Cancer With Recent Therapeutic Advancements for First-line Therapy

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Pharmacists: 0.25 contact hour (0.025 CEUs)

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: November 10, 2025

Expiration: May 09, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Anne Chiang, MD, PhD, FASCO, provides an overview of guideline-directed therapy for ES-SCLC in the first-line setting.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

A 70-year-old man (ECOG PS 1) with a 50 pack-year smoking history presents with weight loss and dyspnea. Imaging reveals a 7-cm right lower lobe lung mass with mediastinal lymphadenopathy and multiple liver metastases. Brain MRI is negative. Lymph node biopsy confirms extensive-stage (ES) small-cell lung cancer (SCLC), positive for synaptophysin, with Ki-67 >80%.

Which of the following treatment plans would you recommend for this patient?

How many people with SCLC do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting: